UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   October 18, 2007

Aastrom Biosciences, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Michigan 000-22025 94-3096597
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
24 Frank Lloyd Wright Drive, P.O. Box 376, Ann Arbor, Michigan   48106
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   (734) 930-5555

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On October 18, 2007, Aastrom Biosciences, Inc. ("Aastrom") issued a press release announcing the presentation of final results from a U.S. Phase I/II clinical trial designed to collect safety and efficacy data utilizing the Company’s Bone Repair Cells (BRCs) in the treatment of severe non-union fractures for patients who have failed prior treatment interventions. Matthew L. Jimenez, M.D., of the Illinois Bone & Joint Institute, presented the final results during a podium presentation at the Orthopaedic Trauma Association annual meeting in Boston, MA. A copy of Dr. Jimenez’ slide presentation is available on Aastrom’s website at www.aastrom.com. A copy of Aastrom’s press release is attached hereto as Exhibit 99.1.





Item 9.01 Financial Statements and Exhibits.





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Aastrom Biosciences, Inc.
          
October 18, 2007   By:   /s/ Gerald D. Brennan, Jr.
       
        Name: Gerald D. Brennan, Jr.
        Title: Vice President, Administrative & Financial Operations and Chief Financial Officer

Exhibit Index


     
Exhibit No.   Description
 
99.1
  Press Release dated October 18, 2007
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vericel Charts.
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vericel Charts.